A detailed history of Aqr Capital Management LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 68,070 shares of VKTX stock, worth $4.48 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
68,070
Previous 39,890 70.64%
Holding current value
$4.48 Million
Previous $3.27 Million 10.34%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $1.34 Million - $2.26 Million
28,180 Added 70.64%
68,070 $3.61 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $131,700 - $715,270
-7,569 Reduced 15.95%
39,890 $3.27 Million
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $75,804 - $161,126
-8,204 Reduced 14.74%
47,459 $883,000
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $264,984 - $388,256
24,266 Added 77.29%
55,663 $616,000
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $465,931 - $778,331
31,397 New
31,397 $508,000
Q2 2022

Aug 15, 2022

BUY
$2.11 - $3.15 $165,489 - $247,057
78,431 Added 178.56%
122,356 $354,000
Q1 2022

May 16, 2022

BUY
$3.0 - $4.88 $131,775 - $214,354
43,925 New
43,925 $132,000
Q3 2019

Nov 14, 2019

SELL
$6.55 - $8.6 $216,844 - $284,711
-33,106 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$7.67 - $10.63 $1,580 - $2,189
206 Added 0.63%
33,106 $275,000
Q1 2019

May 14, 2019

SELL
$7.58 - $9.94 $9,520 - $12,484
-1,256 Reduced 3.68%
32,900 $327,000
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $191,730 - $434,071
-26,778 Reduced 43.95%
34,156 $261,000
Q3 2018

Nov 15, 2018

SELL
$9.7 - $19.65 $179,857 - $364,350
-18,542 Reduced 23.33%
60,934 $1.06 Million
Q2 2018

Aug 14, 2018

BUY
$3.88 - $12.74 $308,366 - $1.01 Million
79,476 New
79,476 $754,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.